0 Comentários
0 Compartilhamentos
26 Visualizações
0 Anterior
Pesquisar
Conheça novas pessoas, crie conexões e faça novos amigos
-
Faça Login para curtir, compartilhar e comentar!
-
MEK Inhibitors Market: How Is Neurofibromatosis Type 1 Approval Creating a New Rare-Disease Revenue Stream?MEK inhibitors targeting neurofibromatosis type 1-associated plexiform neurofibromas — the oral allosteric MEK1/2 inhibitors selumetinib (Koselugo, AstraZeneca) and mirdametinib (Gomekli, SpringWorks Therapeutics) approved for pediatric and adult NF1 patients with symptomatic, inoperable tumors — represent the fastest-growing indication segment in the MEK inhibitor market, with the...0 Comentários 0 Compartilhamentos 190 Visualizações 0 Anterior